» Articles » PMID: 33472729

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

Abstract

Objective: Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.

Methods: A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio ( ) and 95% confidence interval (95% ) of the associations between comorbidities (cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.

Results: Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30-6.32), type 2 diabetes (T2DM) (3.57, 2.32-5.49), cardiovascular disease (CVD) (3.78, 1.81-7.89), fatty liver disease (7.53, 1.96-28.96), hyperlipidemia (2.15, 1.26-3.67), other lung diseases (6.00, 3.01-11.96), and electrolyte imbalance (10.40, 3.00-26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89-12.75), CVD (8.47, 6.03-11.89), and electrolyte imbalance (19.44, 11.47-32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25-9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46-29.64) within two weeks.

Conclusion: Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

Citing Articles

Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.

Shang X, Cao Y, Guo Y, Zhang L, Li J, Zhang H Infect Dis Poverty. 2024; 13(1):97.

PMID: 39696533 PMC: 11658301. DOI: 10.1186/s40249-024-01263-8.


Status and hotspot analysis of Qingfei Paidu Decoction for the prevention and treatment of COVID-19 based on bibliometric analysis.

Zhang H, Liu Y, Shang X, Cao Y, Li J, Chen G Front Pharmacol. 2024; 15:1422773.

PMID: 39144631 PMC: 11322107. DOI: 10.3389/fphar.2024.1422773.


Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.

Jagirdhar G, Qasba R, Pattnaik H, Rama K, Banga A, Reddy S World J Gastroenterol. 2023; 29(21):3362-3378.

PMID: 37377589 PMC: 10292144. DOI: 10.3748/wjg.v29.i21.3362.


Electrolyte imbalances as poor prognostic markers in COVID-19: a systemic review and meta-analysis.

Song H, Chia A, Tan B, Teo C, Lim V, Chua H J Endocrinol Invest. 2022; 46(2):235-259.

PMID: 36070177 PMC: 9449297. DOI: 10.1007/s40618-022-01877-5.


Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series.

Zong X, Liang N, Wang J, Li H, Wang D, Chen Y Front Pharmacol. 2022; 13:849598.

PMID: 35910390 PMC: 9326303. DOI: 10.3389/fphar.2022.849598.


References
1.
Zaim S, Chong J, Sankaranarayanan V, Harky A . COVID-19 and Multiorgan Response. Curr Probl Cardiol. 2020; 45(8):100618. PMC: 7187881. DOI: 10.1016/j.cpcardiol.2020.100618. View

2.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

3.
He Y, Pan A, Wang Y, Yang Y, Xu J, Zhang Y . Prevalence of overweight and obesity in 15.8 million men aged 15-49 years in rural China from 2010 to 2014. Sci Rep. 2017; 7(1):5012. PMC: 5504069. DOI: 10.1038/s41598-017-04135-4. View

4.
Rismanbaf A, Zarei S . Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor. Arch Acad Emerg Med. 2020; 8(1):e17. PMC: 7075271. View

5.
Lorente-Ros A, Monteagudo Ruiz J, Rincon L, Ortega Perez R, Rivas S, Martinez-Moya R . Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. Cardiol J. 2020; 27(5):489-496. PMC: 8078990. DOI: 10.5603/CJ.a2020.0089. View